التفاصيل البيبلوغرافية
| العنوان: |
Therapeutic Vaccination of HIV-1-Infected Patients on Haart with a Recombinant HIV-1 Nef-Expressing Mva: Safety, Immunogenicity and Influence on Viral Load during Treatment Interruption |
| المؤلفون: |
Harrer, Ellen, Bäuerle, Michael, Ferstl, Barbara, Chaplin, Paul, Petzold, Barbara, Mateo, Luis, Handley, Amanda, Tzatzaris, Maria, Vollmar, Jens, Bergmann, Silke, Rittmaier, Marion, Eismann, Kathrin, Müller, Sandra, Kalden, Joachim R, Spriewald, Bernd, Willbold, Dieter, Harrer, Thomas |
| المصدر: |
Antiviral Therapy; February 2005, Vol. 10 Issue: 2 p285-300, 16p |
| مستخلص: |
The safety and immunogenicity of an HIV-1 nef-expressing modified vaccinia virus Ankara (MVA) was investigated in 14 HIV-1-positive patients (CD4 >400/µl) on highly active antiretroviral therapy (HAART). Patients were vaccinated at weeks 0, 4 and 16, followed by interruption of HAART at week 18. MVA-nefwas well-tolerated except for local reactions, with only mild systemic side effects reported in a few patients. Vaccination with MVA-nefwas associated with recognition of new HIV-1 T-cell epitopes (cytotoxic T-lymphocyte epitopes in 9/14 patients, CD4 epitope/recombinant Nef protein in 2/14) and an increase in CD4+ and CD8+ T cells. All patients had been vaccinated against smallpox and a strong T-cell and antibody response to MVA was induced in all patients. After interruption of HAART, viral load rebounded in all patients, but after a median time of 36 (4–76) weeks in 9/14 patients, viraemia remained below the pre-HAART viral load and CD4 counts stayed above the pre-HAART levels. While six patients have remained off therapy for a median time of 64 (57–76) weeks, HAART was resumed in 8/14 patients after a median treatment interruption time of 15 (4–38) weeks. This study has demonstrated that MVA-nefis safe and immunogenic in HIV-1-infected subjects and has provided encouraging data on the potential of therapeutic vaccinations. |
| قاعدة البيانات: |
Supplemental Index |
